Skip to content
DataLookout
Menu

NCT07917832

Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell Lymphoma

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Safety and adverse events (AEs)
Timeframe: Through study completion; an average of 1 year.

Arms and interventions

Group AExperimental

Patients with CR after Cycle 3

Group BExperimental

Patients with less than CR after Cycle 3

Drugs: golcadomide, Obinutuzumab, Polatuzumab, Glofitamab

Sites

1 site in 1 country

  • UT MD Anderson Cancer CenterHouston, Texas, United States